Phase II Trial of the MEK1 and MEK2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas)

syn61259950

Created By NF Service nf-osi-service

studyName: Phase II Trial of the MEK1 and MEK2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas)
dataStatus: Data Pending
initiative: Other
studyLeads: Dr. Brigitte Widemann
studyStatus: Active
diseaseFocus: Neurofibromatosis type 1
grantEndDate: 1812585600000
institutions: NCI Center for Cancer Research
fundingAgency: Other
manifestation: Plexiform Neurofibroma
embargoEndDate: 1749513600000
grantStartDate: 1465516800000
studyFileviewId: syn61259960
syn61259951
syn61259952
syn61259960
syn61259953

Your web browser must have JavaScript enabled in order for this application to display correctly.
If you are an automated web crawler from a search engine, follow this AJAX application crawl link

Phase II Trial of the MEK1 and MEK2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas) page is loading…

Phase II Trial of the MEK1 and MEK2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas)

syn61259950

Drop files to upload

Phase II Trial of the MEK1 and MEK2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas) page is loading…